Cabaletta Bio Inc. Common Stock (CABA)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Cabaletta as a speculative clinical-stage biotech, not a conventional value investment. It has no reported revenue in the filed periods shown. In fiscal 2025, the year ended 2025-12-31, net loss was $167.9 million, or $2.10 per diluted share. That was worse than fiscal 2024, when net loss was $115.9 million, or $2.34 per share, and fiscal 2023, when net loss was $67.7 million, or $1.65 per share. The most recent filed quarter, fiscal Q2 2026 ended 2026-06-30, showed a $51.0 million net loss, or $0.34 per diluted share; fiscal Q1 2026 ended 2026-03-31 lost $43.5 million, or $0.39 per share. So the burn is large and continuing. Business quality? The science may be promising—engineered T-cell therapies for autoimmune diseases—but there is no commercial product, no revenue, and no demonstrated moat. Any competitive advantage is merely potential intellectual property and first-mover hope, which Graham would not capitalize. Financial health is weak. FairStock's TTM free cash flow is -$154.2 million, a -53.8% FCF yield against a $286.5 million market cap at the 2026-10-13 close. Debt is low, with D/E 0.12, but Piotroski is 2/9 and Altman Z is 1.29, both distressed-style readings. ROE is -93.20% and ROCE is -48.19%. The P/E is -1.22, P/B is 1.34, and FairStock score is 26/100. The Lynch category is none because it has lost money each of the last four years. Valuation: at $1.69, near the $1.59 low of its 52-week range, it may look cheap versus book, but there are no earnings to value. Success depends entirely on clinical data. A value investor demands a margin of safety; here the margin is mostly hope.

In plain English: Cabaletta Bio is a clinical-stage healthcare company trying to develop engineered T cell therapies for autoimmune diseases. It has no reported revenue in the filed periods shown and is losing money while burning cash, so the business looks weak by traditional measures. At $1.69 as of 2026-10-13, the stock sits near the low end of its 52-week range, but there is no profit to support the price, so it does not look like a classic bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer